Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).

MLA

Ramos, Juan C., et al. “Impact of Myc in HIV-Associated Non-Hodgkin Lymphomas Treated with EPOCH and Outcomes with Vorinostat (AMC-075 Trial).” Blood, vol. 136, no. 11, Sept. 2020, pp. 1284–97. EBSCOhost, https://doi.org/10.1182/blood.2019003959.

APA

Ramos, J. C., Sparano, J. A., Chadburn, A., Reid, E. G., Ambinder, R. F., Siegel, E. R., Moore, P. C., Rubinstein, P. G., Durand, C. M., Cesarman, E., Aboulafia, D., Baiocchi, R., Ratner, L., Kaplan, L., Capoferri, A. A., Lee, J. Y., Mitsuyasu, R., & Noy, A. (2020). Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood, 136(11), 1284–1297. https://doi.org/10.1182/blood.2019003959

Chicago

Ramos, Juan C, Joseph A Sparano, Amy Chadburn, Erin G Reid, Richard F Ambinder, Eric R Siegel, Page C Moore, et al. 2020. “Impact of Myc in HIV-Associated Non-Hodgkin Lymphomas Treated with EPOCH and Outcomes with Vorinostat (AMC-075 Trial).” Blood 136 (11): 1284–97. doi:10.1182/blood.2019003959.